PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2000British Journal of Cancer327 citationsOpen Access

Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy

VJValerie JenkinsLFLesley Fallowfield

Key Points

Key points are not available for this paper at this time.

Abstract

This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of these 112 (55%) were women with breast cancer. Overall results showed that 147 (72.1%) patients accepted entry to a randomized clinical trial (RCT). The main reasons nominated for participating in a trial were that 'others will benefit' (23.1%) and 'trust in the doctor' (21.1%). One of the main reasons for declining trial entry was that patients were 'worried about randomization' (19.6%). There was a significantly higher acceptance rate for trials providing active treatment in every arm 98 (80.6%) compared with those trials with a no treatment arm 46 (60.5%), chi2 test P= 0.003. The study outlines a number of factors that appear to influence a patient's decision to accept or decline entry into an RCT of cancer therapy. An important factor is whether or not the trial offers active treatment in all arms of the study. Communication that promotes trust and confidence in the doctor is also a powerful motivating influence.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jenkins et al. (2000) studied this question.

synapsesocial.com/papers/69d80a2a5c3030ff03d18c97https://doi.org/10.1054/bjoc.2000.1142
Ask AI
Helpful
Bookmark
Share
View Full Paper